Compare Novartis AG (NVS) vs PepsiCo, Inc. (PEP) Price & Performance

Novartis AGTrade

PepsiCo, Inc.Trade

Price performance (Past 24H)

Key statistics

Novartis AG vs PepsiCo, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while PepsiCo, Inc. trades at $134.9 (market cap $184.89B). The key difference: Novartis AG is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.

	NVS	PEP
Market Cap	$290.25B	$184.89B
Sector	Health	Consumer Staples
52-Week High	$168.62	$170.44
52-Week Low	$113.50	$135.40
Enterprise Value	$330.27B	$227.39B
Dividend Yield	3.17%	4.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

PepsiCo, Inc.

PepsiCo (PEP) trades at $134.98, down 1.56% over 24 hours, with a bearish technical signal and support near $130. The company reported revenue of $93.93B in 2025 and has beaten EPS estimates in recent quarters. Analysts maintain a consensus price target of $158.50, with 33% buy ratings. Recent news highlights price cuts on snacks like Doritos to address consumer pushback on high prices.

PEP offers a stable dividend and strong profitability with a 10.78% net margin, but faces risks from inflation and competitive pressures. The stock's current valuation below consensus target suggests potential upside if North American performance improves, though near-term technical weakness may persist.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

PEP

July's top 5 dividend stocks offer 16.3% returns and 6.0% yield, with PepsiCo rated Strong Buy.Seeking Alpha · 3 days agoBullish PepsiCo raises quarterly dividend 4% to $1.48 per share, continuing 54 years of annual increases.PRNewsWire · 4 days agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About PepsiCo, Inc.

PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.